Sweden's ADDvise Q4 prelim revenue misses estimates

ADDvise AB (publ)

14/01/2026 16:00

Overview

Life science group's preliminary Q4 revenue fell 4.5% organically, missing analyst expectations

Preliminary Q4 EBITA rose 6.7% to SEK 80 mln

Preliminary full-year net sales decreased 3.9% organically, but increased 1.5% with currency adjustments

Outlook

Company did not provide specific guidance for future quarters or years in the press release

Result Drivers

CURRENCY EFFECTS - Adjusted for currency effects, Q4 net revenue increased by 4.0% despite an organic decrease

EBITA GROWTH - Preliminary Q4 EBITA rose 6.7% to SEK 80 mln

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
Miss
SEK 422 mln
SEK 431 mln (2 Analysts)
Q4 EBITA
SEK 80 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for ADDvise Group AB (publ) is SEK1.72, about 3.6% above its January 13 closing price of SEK1.66

The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 13 three months ago

Press Release: ID:nMFN4D1GMX

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)